|
#466
26.06.2013, 18:17
|
|||
|
|||
|
Öèòàòà:
|
|
#467
04.07.2013, 20:06
|
|||
|
|||
|
×òî-òî ÿ "çàðàáîòàëñÿ"... :-(
Äîïîìîæèòü, áóäü ëàñêà?  To investigate whether a possible imbalance in patient characteristics between arms may have influenced the survival results, a Cox regression model was fitted with covariates whose individual univariate log-rank P values were ≤0.10
|
|
#470
13.07.2013, 15:37
|
|||
|
|||
|
Äîáðîãî äíÿ ëþáèòåëÿì àãëèöêîé ñëîâåñíîñòè!
Treatment-related death: death due to drug toxicity not to disease progression, reported as ’treatment-related’, ’toxic death’ or ’lethal toxicity’ Åñòü â ðóññêîì êàêîé ëèáî àíàëîã âûäåëåííîìó? (Ñìåðòåëüíàÿ èíòîêñèêàöèÿ?) Èëè îí èäåíòè÷åí òðåòüåìó îïðåäåëåíèþ - "ñìåðòåëüíàÿ òîêñè÷íîñòü" È ÷òî òàêîå ïî ðóññêè - "ñåðàÿ" ëèòåðàòóðà"??? (êàê è ñåðûå òåëåôîíû?? :-) We limited our search to articles (conventional and grey literature) Grey literature is created by researchers and practitioners in various fields, but is not controlled by commercial publishing. The groups that produce grey literature may be government, industry, advocacy or other organizations that disseminate information in the form of reports or working papers rather than by publishing scholarly articles in commercial journals. Grey literature can be found in the form of: reports conference papers, posters or proceedings policy documents preprints data sets standards translations clinical trial data factsheets dissertations committee reports and more More often than not, grey literature is not indexed in databases and so can be a puzzle to find. Locating grey literature can be a very different process than locating scholarly articles.
|
|
#471
13.07.2013, 17:41
|
||||
|
||||
|
Ìîæíî "ñìåðòü èç-çà èíòîêñèêàöèè": âñå òðè òåðìèíà ïðèìåðíî îá îäíîì è òîì æå...
âòîðîé - "íå èíäåêñèðîâàííàÿ â ìåä. áàçàõ äàííûõ ëèòåðàòóðà"
|
|
#472
13.07.2013, 21:38
|
|||
|
|||
|
Öèòàòà:
(ôèëèí, áëèí....  )Ñïñ. Òåïåðü âîò "case-mix adjustment" âûçûâàåò ïàðàëè÷ èçâèëèí. we will separately assess the methodological quality of observational studies by using a component approach considering: concurrent, concomitant treatment; how allocation occurred; any attempt to balance groups by design; blinding of outcome assessment; completeness of follow-up; identification of prognostic factors (e.g. cardiovascular risk factors); and case-mix adjustment
|
|
#476
21.07.2013, 23:24
|
|||
|
|||
|
Öèòàòà:
|
|
#477
27.07.2013, 19:37
|
|||
|
|||
|
Íåò ê ðèñóíêàì è â òåêñòå ïîÿñíåíèé, ïîñåìó ïðîøó ìíåíèé:
[Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] SE - ñòàíäàðòíàÿ îøèáêà Weight - âåñ èëè âñå æå âçâåøåííàÿ? log (Hazard ratio) - Ëîã (Êîýôèöèåíò ðèñêà)? - Ïàðàìåòð? ? IV - Independent Variable? Random - ïðîèçâîëüíûé? df - Degrees of freedom ?
|
|
#478
28.07.2013, 11:15
|
|||
|
|||
|
SE - standard error, ñòàíäàðòíàÿ îøèáêà
Weight - âåñîâîé êîýôôèöèåíò, âåñ êîíêðåòíîãî èññëåäîâàíèÿ â ïðîâîäèìîì ìåòà-àíàëèçå log (Hazard ratio) - íàòóðàëüíûé ëîãàðèôì îòíîøåíèÿ ðèñêîâ df - ÷èñëî ñòåïåíåé ñâîáîäû IV è Random - ðå÷ü èä¸ò î ñïîñîáàõ ïðîâåäåíèÿ Random-effects meta-analyses: åñòü ìåòîä Mantel-Haenszel (M-H) Random, åñòü Inverse variance (IV) Random. Ïî-ðóññêè âìåñòî IV Random äîëæíî ïîëó÷èòüñÿ ÷òî-òî òèïà "ìîäåëü ñî ñëó÷àéíûìè ýôôåêòàìè, ìåòîä îáðàòíîé äèñïåðñèè" (ñì. òàêæå [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]).
|
|
#479
28.07.2013, 17:09
|
|||
|
|||
|
Öèòàòà:
|
|
#480
04.08.2013, 20:27
|
||||
|
||||
|
Óâ. êîëëåãè, â ïåðâóþ î÷åðåäü èíôåêöèîíèñòû, ïîìîãèòå, ïîæàëóéñòà.
"In contrast, in patients with nucleos(t)ide therapy the measurement of qHBsAg levels over time have not yielded definite answers yet in helping to distinguish patients that will clinically resolve chronic hepatitis B infection with HBsAg loss or seroconversion". Íàïðîòèâ, ó ïàöèåíòîâ íà òåðàïèè àíàëîãàìè íóêëåîçèäîâ èçìåðåíèå óðîâíÿ qHBsAg ñ òå÷åíèåì âðåìåíè íå äàëî ïîêà îïðåäåëåííîãî îòâåòà ... äàëåå äëÿ ìåíÿ íåïîíÿòíàÿ êîìáèíàöèÿ ïîíÿòíûõ ïî îòäåëüíîñòè ñëîâ íå ïîçâîëÿåò âûÿâèòü ïàöèåíòîâ, êîòîðûå ïðîäåìîíñòðèðóþò ïîëîæèòåëüíûé îòâåò íà òåðàïèþ ñ èñ÷åçíîâåíèåì HBsAg èëè ñåðîêîíâåðñèåé?
|
Ëèíåéíûé âèä
